Sigyn Therapeutics Stock News

The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier Sarasota, FL and San

Sigyn Therapeutics (OTCMKTS:SIGY - Get Free Report) and Shuttle Pharmaceuticals (NASDAQ: SHPH - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compa

Presentation on Tuesday, October 21st at 4:00 PM PT San Diego, California--(Newsfile Corp. - October 21, 2025) - Sigyn Therapeutics, Inc. (OTCQB: SIGY), a developer of dialysis-like therapies to addre

Presentation on Tuesday, October 21st at 4:00 PM PT San Diego, California--(Newsfile Corp. - October 17, 2025) - Sigyn Therapeutics, Inc. (OTCQB: SIGY), a developer of dialysis-like therapies to addre

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as

Underfollowed Innovator to Enjoy Profile Raise BALTIMORE, MD / ACCESS Newswire / July 1, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sect

Underfollowed Innovator to Enjoy Profile Raise BALTIMORE, MD / ACCESS Newswire / July 1, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sect

SAN DIEGO, CA -- March 12, 2025 -- InvestorsHub NewsWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY) today released the following note authored by its CEO, Jim Joyce. Dear Reader, Blood purification technologies have emerged to become leading post-exposure countermeasures to treat emerging pandemic viruses.  When properly designed, these devices can also serve a dual-use purpose in everyday medicine.  In this regard, Sigy...

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as

Live Online Presentation Scheduled at 12 pm EST on March 6 th SAN DIEGO, CA, March 05, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn Therapeutics” or the “Company

SAN DIEGO, CA, Feb. 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (“Sigyn Therapeutics” or the “Company”) (OTCQB: “SIGYD” – “SIGY”), a development-stage

SAN DIEGO, CA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire –Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: “SIGYD”, “SIGY”), a development-stage medical technolog

SAN DIEGO, CA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today an

SAN DIEGO, CA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today an

SAN DIEGO, CA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today an